Breakthrough Pain Management with IV Hydromorphone
Dosing Guidelines
- The National Comprehensive Cancer Network recommends that breakthrough doses should equal 10-20% of the total 24-hour opioid requirement, calculated in morphine equivalents and converted to hydromorphone, for opioid-tolerant patients 1, 2, 3
- For patients receiving around-the-clock opioids, the breakthrough dose can be calculated by converting their total daily dose to IV hydromorphone equivalents (using a 5:1 morphine-to-hydromorphone ratio) and providing 10-20% of that total as the rescue dose 1, 3
Reassessment and Titration Protocol
- The National Comprehensive Cancer Network suggests that efficacy and adverse effects must be assessed every 15 minutes for IV opioids to determine subsequent dosing 1, 2
- If pain remains unchanged or worsens after 15 minutes, administer 50-100% of the previous rescue dose (0.5-1mg additional if the initial dose was 1mg) and continue reassessing every 15 minutes 1, 2
Critical Safety Considerations
- The National Comprehensive Cancer Network recommends prophylactically prescribing stimulant laxatives with or without stool softeners for all patients receiving opioids, as constipation is nearly universal 1, 3
Common Pitfalls to Avoid
- The National Comprehensive Cancer Network advises against using extended-release or controlled-release formulations for breakthrough pain—only immediate-release formulations like IV hydromorphone are appropriate 2, 4
- The National Comprehensive Cancer Network suggests not withholding adequate breakthrough dosing out of fear of overdose in opioid-tolerant patients—these patients require higher doses proportional to their baseline opioid consumption 1, 2